NOFUN

Novel antifungals to treat resistant organisms

Coordinatore	THE UNIVERSITY OF MANCHESTER    more  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: 441613000000
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	6˙106˙868 €
EC contributo	4˙550˙286 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-07-01   -   2016-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: 441613000000	UK (MANCHESTER)	coordinator	1˙251˙570.00
2	F2G Ltd  Organization address address: PO Box 1 Lankro Way 1 city: MANCHESTER postcode: M30 0BH contact info Titolo: Dr. Nome: Michael Cognome: Birch Email: send email Telefono: +44 1617851271	UK (MANCHESTER)	participant	1˙214˙095.00
3	ONCO TARGETING AB  Organization address address: VIRDINGS ALLE 32 B city: UPPSALA postcode: 754 50 contact info Titolo: Dr. Nome: Fredrik Cognome: Lehmann Email: send email Telefono: +46 76 614 8739	SE (UPPSALA)	participant	974˙496.00
4	UNIVERSITAT ROVIRA I VIRGILI  Organization address address: CARRER DE ESCORXADOR city: TARRAGONA postcode: 43003 contact info Titolo: Prof. Nome: Josep Cognome: Guarro Email: send email Telefono: +34 977759359	ES (TARRAGONA)	participant	677˙676.00
5	PHARMACELSUS GMBH  Organization address address: SCIENCE PARK 2 city: SAARBRUCKEN postcode: 66123 contact info Nome: Rüdiger Cognome: Ullrich Email: send email Telefono: +49 68139467510 Fax: +49 681 3946 7511	DE (SAARBRUCKEN)	participant	432˙449.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Invasive fungal diseases are estimated to kill 1.5 million people each year. The incidence of mortality has risen significantly across the EU over the last 20 years due to an expansion of at risk patient populations. Given the obvious importance of these diseases it is perhaps surprising that only four classes of drug are available to treat systemic fungal infection. The azole class of antifungals provide the front line role for most disease treatment but recently resistance has emerged and it is of growing concern that levels are rising dramatically. European researchers have led the world in identifying the extent of the problem with some centres reporting itraconazole resistance in the Aspergillus species as high as 20% and in Candida, resistance to posaconazole upto 30%. Additionally the epidemiology of serious fungal infections is changing with more intrinsically resistant organisms now being seen more frequently. This represents a major problem for clinicians who are increasingly treating infections for which there is no current effective therapy. This proposal brings together leading European SME’s and academics to address this problem through the development of novel classes of antifungals and the identification of novel drug targets. The NOFUN consortium has identified potent novel broad spectrum antifungal molecules that are active against multi-resistant fungal pathogens and intends to qualify these as drug candidates. One of these assets is already at the lead identification stage. Cutting edge fungal genomics will be used to identify novel druggable targets and advance these to develop qualified tractable chemical inhibitors. With its wide ranging expertise across medicinal chemistry, ADMET, fungal biology, chemical genomics and drug development the partners will build and progress a broad pipeline of agents that have the potential to reach the clinic within 5 years.'